2
|
Gotru SK, Mammadova-Bach E, Sogkas G, Schuhmann MK, Schmitt K, Kraft P, Herterich S, Mamtimin M, Pinarci A, Beck S, Stritt S, Chao H, Ren P, Freund JN, Klemann C, Ringshausen FC, Heemskerk JWM, Dietrich A, Nieswandt B, Stoll G, Gudermann T, Braun A. MAGT1 Deficiency Dysregulates Platelet Cation Homeostasis and Accelerates Arterial Thrombosis and Ischemic Stroke in Mice. Arterioscler Thromb Vasc Biol 2023. [PMID: 37381987 DOI: 10.1161/atvbaha.122.318115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/30/2023]
Abstract
BACKGROUND MAGT1 (magnesium transporter 1) is a subunit of the oligosaccharide protein complex with thiol-disulfide oxidoreductase activity, supporting the process of N-glycosylation. MAGT1 deficiency was detected in human patients with X-linked immunodeficiency with magnesium defect syndrome and congenital disorders of glycosylation, resulting in decreased cation responses in lymphocytes, thereby inhibiting the immune response against viral infections. Curative hematopoietic stem cell transplantation of patients with X-linked immunodeficiency with magnesium defect causes fatal bleeding and thrombotic complications. METHODS We studied the role of MAGT1 deficiency in platelet function in relation to arterial thrombosis and hemostasis using several in vitro experimental settings and in vivo models of arterial thrombosis and transient middle cerebral artery occlusion model of ischemic stroke. RESULTS MAGT1-deficient mice (Magt1-/y) displayed accelerated occlusive arterial thrombus formation in vivo, a shortened bleeding time, and profound brain damage upon focal cerebral ischemia. These defects resulted in increased calcium influx and enhanced second wave mediator release, which further reinforced platelet reactivity and aggregation responses. Supplementation of MgCl2 or pharmacological blockade of TRPC6 (transient receptor potential cation channel, subfamily C, member 6) channels, but not inhibition of store-operated calcium entry, normalized the aggregation responses of Magt1-/y platelets to the control level. GP (glycoprotein) VI activation of Magt1-/y platelets resulted in hyperphosphorylation of Syk (spleen tyrosine kinase), LAT (linker for activation of T cells), and PLC (phospholipase C) γ2, whereas the inhibitory loop regulated by PKC (protein kinase C) was impaired. A hyperaggregation response to the GP VI agonist was confirmed in human platelets isolated from a MAGT1-deficient (X-linked immunodeficiency with magnesium defect) patient. Haploinsufficiency of TRPC6 in Magt1-/y mice could normalize GP VI signaling, platelet aggregation, and thrombus formation in vivo. CONCLUSIONS These results suggest that MAGT1 and TRPC6 are functionally linked. Therefore, deficiency or impaired functionality of MAGT1 could be a potential risk factor for arterial thrombosis and stroke.
Collapse
Affiliation(s)
- Sanjeev Kiran Gotru
- Institute of Experimental Biomedicine, University Hospital and Rudolf Virchow Center, University of Würzburg, Germany. (S.K.G., K.S., S.B., S.S., B.N., A.B.)
| | - Elmina Mammadova-Bach
- Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany (E.M.-B., M.M., A.P., H.C., A.D., T.G., A.B.)
- Division of Nephrology, Department of Medicine IV, Ludwig-Maximilians University Hospital, Munich, Germany (E.M.-B., M.M., H.C.)
| | - Georgios Sogkas
- Cluster of Excellence RESIST, Hannover Medical School (MHH), Germany. (G. Sogkas)
- Rheumatology and Immunology, Hannover Medical School (MHH), Germany. (G. Sogkas)
| | - Michael K Schuhmann
- Department of Neurology, University Hospital of Würzburg, Germany (M.K.S., P.K., G. Stoll)
| | - Karen Schmitt
- Institute of Experimental Biomedicine, University Hospital and Rudolf Virchow Center, University of Würzburg, Germany. (S.K.G., K.S., S.B., S.S., B.N., A.B.)
| | - Peter Kraft
- Department of Neurology, University Hospital of Würzburg, Germany (M.K.S., P.K., G. Stoll)
- Department of Neurology, Hospital Main-Spessart, Lohr, Germany (P.K.)
| | - Sabine Herterich
- Institute for Clinical Biochemistry and Pathobiochemistry, University of Würzburg, Germany. (S.H.)
| | - Medina Mamtimin
- Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany (E.M.-B., M.M., A.P., H.C., A.D., T.G., A.B.)
- Division of Nephrology, Department of Medicine IV, Ludwig-Maximilians University Hospital, Munich, Germany (E.M.-B., M.M., H.C.)
| | - Akif Pinarci
- Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany (E.M.-B., M.M., A.P., H.C., A.D., T.G., A.B.)
| | - Sarah Beck
- Institute of Experimental Biomedicine, University Hospital and Rudolf Virchow Center, University of Würzburg, Germany. (S.K.G., K.S., S.B., S.S., B.N., A.B.)
| | - Simon Stritt
- Institute of Experimental Biomedicine, University Hospital and Rudolf Virchow Center, University of Würzburg, Germany. (S.K.G., K.S., S.B., S.S., B.N., A.B.)
| | - Han Chao
- Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany (E.M.-B., M.M., A.P., H.C., A.D., T.G., A.B.)
- Division of Nephrology, Department of Medicine IV, Ludwig-Maximilians University Hospital, Munich, Germany (E.M.-B., M.M., H.C.)
| | - Pengxuan Ren
- School of Life Science and Technology, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, China (P.R.)
| | - Jean-Noël Freund
- INSERM, IRFAC/UMR-S1113, FMTS, University of Strasbourg, France (J.-N.F.)
| | - Christian Klemann
- Department of Women and Child Health, Center of Pediatric Research (CPL), Hospital for Children and Adolescents, Leipzig University, Germany (C.K.)
| | - Felix C Ringshausen
- Department of Respiratory Medicine, Hannover Medical School (MHH), Germany. (F.C.R.)
- Biomedical Research in Obstructive and End-Stage Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Germany (F.C.R.)
| | - Johan W M Heemskerk
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands (J.W.M.H.)
| | - Alexander Dietrich
- Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany (E.M.-B., M.M., A.P., H.C., A.D., T.G., A.B.)
| | - Bernhard Nieswandt
- Institute of Experimental Biomedicine, University Hospital and Rudolf Virchow Center, University of Würzburg, Germany. (S.K.G., K.S., S.B., S.S., B.N., A.B.)
| | - Guido Stoll
- Department of Neurology, University Hospital of Würzburg, Germany (M.K.S., P.K., G. Stoll)
| | - Thomas Gudermann
- Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany (E.M.-B., M.M., A.P., H.C., A.D., T.G., A.B.)
| | - Attila Braun
- Institute of Experimental Biomedicine, University Hospital and Rudolf Virchow Center, University of Würzburg, Germany. (S.K.G., K.S., S.B., S.S., B.N., A.B.)
- Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians University, Munich, Germany (E.M.-B., M.M., A.P., H.C., A.D., T.G., A.B.)
| |
Collapse
|
3
|
An P, Dong S, Li X, Cai Z, Ye B, Zhang A, Shi X, Wu X. Wenyang Huazhuo Fang exerts transient receptor potential cation channel subfamily C member-dependent nephroprotection in a rat model of doxorubicin-induced nephropathy. J TRADIT CHIN MED 2021; 40:613-620. [PMID: 32744028 DOI: 10.19852/j.cnki.jtcm.2020.04.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To determine the effect of Wenyang Huazhuo Fang (WHF), a Traditional Chinese Medicine decoction, on renal function in a rat model of doxorubicin-induced nephropathy, and to elucidate the underlying mechanism. METHODS Sprague-Dawley rats were randomly divided into six groups: control, doxorubicin-nephropathy, and prednisone-treated (6.45 mg·kg-1·d-1) doxorubicin nephropathy groups, as well as high- (7.26 g·kg-1·d-1, medium- (2.42 g·kg-1·d-1, and low-dose (0.81 g·kg-1·d-1 WHF-treated doxorubicin-nephropathy groups. The nephropathy rat model was established by two tail vein injections of doxorubicin, followed by prednisone or WHF treatment for 8 weeks. Body weights were monitored and urinary protein was measured every 2 weeks. After the end of the treatment period, the rats were euthanized. Serum biochemical indicators were determined and renal morphological alterations were assessed using histological staining. The expression of transient receptor potential cation channel subfamily C member 6 (TRPC6), stromal interaction molecule 1 (STIM1), and calcium release-activated calcium channel protein 1 (Orai1) was detected using western blotting, and their mRNA levels were examined using quantitative real-time reverse transcription-polymerase chain reaction. RESULTS WHF treatment was found to significantly ameliorate weight loss, proteinuria, hypoalbuminemia, and dyslipidemia in doxorubicin-nephropathy rats. The protein and mRNA levels of TRPC6, STIM1, and Orai1 were partially, but significantly suppressed by prednisone or WHF treatment. CONCLUSION Treatment with WHF significantly ameliorates renal injury in a rat model of doxorubicin-induced nephropathy, which could be at least partially related to repression of the TRPC6 pathway.
Collapse
Affiliation(s)
- Peng An
- Department of Integrated Chinese Traditional and Western Medicine, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - Sheng Dong
- Department of Nephropathy, the Affiliated Hospital of Shaan Xi University of Chinese Medicine, Xianyang 712023, China
| | - Xingyao Li
- Department of Integrated Chinese Traditional and Western Medicine, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - Zimo Cai
- Department of Integrated Chinese Traditional and Western Medicine, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - Bingyu Ye
- Department of Integrated Chinese Traditional and Western Medicine, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - Aijun Zhang
- Department of Pharmacy, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an710082, China
| | - Xingmin Shi
- Department of Immunology, Xi'an Jiaotong University Health Science Center, Xi'an 710061, China
| | - Xili Wu
- Department of Integrated Chinese Traditional and Western Medicine, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| |
Collapse
|